A multi-center randomized controlled study on the safety and efficacy of micro hyperbaric oxygen therapy on viral nucleic acid negative conversion in patients with COVID-19 infection

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060487

Enrollment

Unknown

Registered

2022-06-03

Start date

2022-04-20

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Micro hyperbaric oxygen therapy + routine isolation course

Control group:Routine isolation course

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 75 years; 2. SARS-CoV-2 nucleic acid test positive; 3. Within 5 days after a positive nucleic acid test; 4. Able to complete the operation of micro-hyperbaric oxygen therapy chamber under the guidance; 5. There is no absolute contraindication to high pressure exposure; 6. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients. 2. Claustrophobia. 3. Asymptomatic patients. 4. Patients deemed unsuitable for the trial for other reasons.

Design outcomes

Primary

Measure	Time frame
Time of SARS-CoV-2 nucleic acid test turning negative;	—

Secondary

Measure	Time frame
Viral load (CT value);Routine blood;IL-1ß;IL-6;C-reactive protein;TNF-a;D-dimer (D2D);Serum IgE;Serum IgG;Fatigue self-rating scale for fatigue;The Baker anxiety scale for anxiety;The Baker depression scale for depression;	—

Countries

China

Contacts

Public ContactLiu Yang

Department of Critical Care Medicine, Naval Medical Center of PLA

liuyang3722@163.com+86 13761105709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026